2 terminated, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Active not recruiting 1 |
Follow Splenomegaly: new trials by email Literature Review of Splenomegaly trials Research Report on Splenomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
Anemia (3) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Primary Myelofibrosis (3) · Hemorrhagic Disorders (2) · Myeloproliferative Disorders (2) · Polycythemia Vera (2) · Thrombocythemia, Essential (2) · Thrombocytopenia (2) · Blood Platelet Disorders (1)
Hemic and Lymphatic Diseases (3) · Hypertrophy (3) · Pathological Conditions, Anatomical (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Bone Marrow Neoplasms (2) · Cytopenia (2) · Hematologic Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Thrombocytosis (2) · Hemorrhagic Disorders (1) · Myeloproliferative Disorders (1)
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (3) · Adrenal Cortex Hormones (1) · Danazol (1) · Hydroxyurea (1) · ruxolitinib (1)
CTI BioPharma (2) · Swedish Orphan Biovitrum (1)
Australia (3) · Czechia (3) · France (3) · Hungary (3) · Russia (3) · United Kingdom (3) · United States (3) · Belgium (2) · Canada (2) · Germany (2) · Italy (2) · Netherlands (2) · New Zealand (2) · Belarus (1) · Bosnia and Herzegovina (1)
Simran Singh (2) · Beth Ziemba (1)
PMID 33275766, PMID 33232476, PMID 34551507, PMID 39400386, PMID 42316774